EP0868196A4 - Synthetic vaccine for protection against human immunodeficiency virus infection - Google Patents

Synthetic vaccine for protection against human immunodeficiency virus infection

Info

Publication number
EP0868196A4
EP0868196A4 EP96936830A EP96936830A EP0868196A4 EP 0868196 A4 EP0868196 A4 EP 0868196A4 EP 96936830 A EP96936830 A EP 96936830A EP 96936830 A EP96936830 A EP 96936830A EP 0868196 A4 EP0868196 A4 EP 0868196A4
Authority
EP
European Patent Office
Prior art keywords
protection against
immunodeficiency virus
virus infection
human immunodeficiency
against human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96936830A
Other languages
German (de)
French (fr)
Other versions
EP0868196A1 (en
Inventor
Barton F Haynes
Thomas J Palker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/546,515 external-priority patent/US5993819A/en
Application filed by Duke University filed Critical Duke University
Publication of EP0868196A1 publication Critical patent/EP0868196A1/en
Publication of EP0868196A4 publication Critical patent/EP0868196A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP96936830A 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection Withdrawn EP0868196A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US546515 1995-10-20
US08/546,515 US5993819A (en) 1987-09-08 1995-10-20 Synthetic vaccine for protection against human immunodeficiency virus infection
US59926696A 1996-02-09 1996-02-09
US599266 1996-02-09
PCT/US1996/016911 WO1997014436A1 (en) 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection

Publications (2)

Publication Number Publication Date
EP0868196A1 EP0868196A1 (en) 1998-10-07
EP0868196A4 true EP0868196A4 (en) 2004-11-24

Family

ID=27068273

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96936830A Withdrawn EP0868196A4 (en) 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection

Country Status (5)

Country Link
EP (1) EP0868196A4 (en)
JP (1) JPH11515006A (en)
AU (1) AU7465696A (en)
CA (1) CA2235168A1 (en)
WO (1) WO1997014436A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814925C2 (en) * 1998-04-03 2000-10-05 Thomas Harrer Medicinal products for induction of cytotoxic T cells
MXPA02007478A (en) * 2000-02-04 2004-08-23 Univ Duke Human immunodeficiency virus vaccine.
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
MXPA03002480A (en) 2000-09-22 2004-05-24 Univ Duke Immunogen comprising ligand bound hiv envelpe protein.
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
CA2466050A1 (en) 2001-11-07 2003-05-15 Duke University Polyvalent immunogen
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
CA2669049A1 (en) * 2006-11-09 2008-11-06 Sudhir Paul Binary epitope antibodies and b cell superantigen immune stimulants
US7892562B2 (en) 2008-10-08 2011-02-22 Karp Nelson M Methods of inducing TH-1 immune responses to HIV-1 by administering UV/psoralen-treated desialated inactiviated HIV-1 virions deficient in CD55 and CD59
EP3518968B1 (en) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227169A2 (en) * 1985-12-17 1987-07-01 Akzo N.V. Immunochemical reagent
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
EP0387914A1 (en) * 1984-10-18 1990-09-19 Institut Pasteur Envelope antigens of the human immuno-deficiency virus, and their applications
WO1995029700A1 (en) * 1994-04-29 1995-11-09 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387914A1 (en) * 1984-10-18 1990-09-19 Institut Pasteur Envelope antigens of the human immuno-deficiency virus, and their applications
EP0227169A2 (en) * 1985-12-17 1987-07-01 Akzo N.V. Immunochemical reagent
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
WO1995029700A1 (en) * 1994-04-29 1995-11-09 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GROENINK M ET AL: "PHENOTYPE-ASSOCIATE ENV GENE VARIATION AMONG EIGHT RELATED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CLONES: EVIDENCE FOR IN VIVO RECOMBINATION AND DETERMINANTS OF CYTOTROPISM OUTSIDE THE V3 DOMAIN", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 10, October 1992 (1992-10-01), pages 6175 - 6180, XP009019329, ISSN: 0022-538X *
LOPALCO L ET AL: "IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 GLYCOPROTEIN GP120/GP41 INTERACTION SITES BY THE IDIOTYPIC MIMICRY OF TWO MONOCLONAL ANTIBODIES", AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW YORK, NY, US, vol. 9, no. 1, January 1993 (1993-01-01), pages 33 - 39, XP001059095, ISSN: 0889-2229 *
NEURATH A R ET AL: "SYNTHETIC PEPTIDES AND ANTI-PEPTIDE ANTIBODIES AS PROBES TO STUDY INTERDOMAIN INTERACTIONS INVOLVED IN VIRUS ASSEMBLY THE ENVELOPE OF THE HUMAN IMMUNODEFICIENCY VIRUS HIV-1", VIROLOGY, vol. 188, no. 1, 1992, pages 1 - 13, XP008035866, ISSN: 0042-6822 *
PALKER T ET AL: "Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 142, no. 10, 15 May 1989 (1989-05-15), pages 3612 - 3619, XP002158688, ISSN: 0022-1767 *
See also references of WO9714436A1 *
STAMAMTATOS LEONIDAS ET AL: "Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1", JOURNAL OF VIROLOGY, vol. 68, no. 8, 1994, pages 4973 - 4979, XP002297224, ISSN: 0022-538X *

Also Published As

Publication number Publication date
JPH11515006A (en) 1999-12-21
CA2235168A1 (en) 1997-04-24
WO1997014436A1 (en) 1997-04-24
EP0868196A1 (en) 1998-10-07
AU7465696A (en) 1997-05-07

Similar Documents

Publication Publication Date Title
AU5726694A (en) Human immunodeficiency virus decoy
AP9701060A0 (en) Hepatitis B vaccine
HK1008982A1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
ZA924150B (en) Vaccine for human immunodeficiency virus
HUP9601466A2 (en) Adjuvants for viral vaccines
HUP9601462A2 (en) Adjuvants for viral vaccines
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
EP0868196A4 (en) Synthetic vaccine for protection against human immunodeficiency virus infection
HU9300010D0 (en) Glycoprotein vaccine named ehv-4
GB9210337D0 (en) Feline leukaemia virus vaccine
EP0967993A4 (en) Anti-cocaine vaccine
ZA96722B (en) Combination therapy for hiv infection
AU1194997A (en) Plasmid vaccine against pseudorabies virus
ZA955269B (en) Combination therapy for HIV infection
EP0942748A4 (en) Env-glycoprotein vaccine for protection of htlv-i and -ii infection
AU8096998A (en) Attenuated human immunodeficiency virus vaccine
AU5398296A (en) Vaccine for the immunoprophylaxis of the infection from feli ne immunodeficiency virus in the domestic cat
GB9702990D0 (en) Virus vaccine
IL115197A0 (en) Vaccine preparations
GB9526433D0 (en) Vaccine component
EP0624372A3 (en) Medicament for treating human immunodeficiency virus.
GB9514118D0 (en) Novel attenvated HIV vaccine
AU5732594A (en) Human aids vaccine from revertant cattle virus
GB9620856D0 (en) Virus vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/16 B

Ipc: 7A 61K 38/16 B

Ipc: 7G 01N 33/567 B

Ipc: 7G 01N 33/53 B

Ipc: 7C 12Q 1/70 B

Ipc: 7A 61K 38/04 B

Ipc: 7A 61K 38/00 B

Ipc: 7A 61K 39/21 A

A4 Supplementary search report drawn up and despatched

Effective date: 20041011

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041224